Amgen will buy a blockbuster psoriasis drug for $13.4 billion — and it’s part of a plan to get Celgene’s mega-merger with Bristol-Myers Squibb approved

Celgene agreed to a $74 billion merger with Bristol-Myers Squibb back in January 2019, and it's still awaiting regulatory approval.